HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/5/R1855    most recent 00297.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mack, C. Articles by Parkes, D. Search for Related Content PubMed PubMed Citation Articles by Mack, C. Articles by Parkes, D.

APPETITE, OBESITY, DIGESTION, AND METABOLISM

Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight

Amylin Pharmaceuticals, Inc., San Diego, California

Submitted 27 April 2007 ; accepted in final form 7 September 2007

The ability of amylin to reduce acute food intake in rodents is well established. Longer-term administration in rats (up to 24 days) shows a concomitant reduction in body weight, suggesting energy intake plays a significant role in mediating amylin-induced weight loss. The current set of experiments further explores the long-term effects of amylin (4–11 wk) on food preference, energy expenditure, and body weight and composition. Furthermore, we describe the acute effect of amylin on locomotor activity and kaolin consumption to test for possible nonhomeostatic mechanisms that could affect food intake. Four-week subcutaneous amylin infusion of high-fat fed rats (3–300 µg·kg^–1·day^–1) dose dependently reduced food intake and body weight gain (ED₅₀ for body weight gain = 16.5 µg·kg^–1·day^–1). The effect of amylin on body weight gain was durable for up to 11 wks and was associated with a specific loss of fat mass and increased metabolic rate. The body weight of rats withdrawn from amylin (100 µg·kg^–1·day^–1) after 4 wks of infusion returned to control levels 2 wks after treatment cessation, but did not rebound above control levels. When self-selecting calories from a low- or high-fat diet during 11 wks of infusion, amylin-treated rats (300 µg·kg^–1·day^–1) consistently chose a larger percentage of calories from the low-fat diet vs. controls. Amylin acutely had no effect on locomotor activity or kaolin consumption at doses that decreased food intake. These results demonstrate pharmacological actions of amylin in long-term body weight regulation in part through appetitive-related mechanisms and possibly via changes in food preference and energy expenditure.

body composition; meal size; locomotor activity; kaolin consumption; pramlintide

This article has been cited by other articles:

				J. D. Roth, H. Maier, S. Chen, and B. L. Roland Implications of Amylin Receptor Agonism: Integrated Neurohormonal Mechanisms and Therapeutic Applications Arch Neurol, March 1, 2009; 66(3): 306 - 310. [Full Text] [PDF]

				S. R. Smith, L. J. Aronne, C. M. Burns, N. C. Kesty, A. E. Halseth, and C. Weyer Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity Diabetes Care, September 1, 2008; 31(9): 1816 - 1823. [Abstract] [Full Text] [PDF]

				R. D. Reidelberger, A. C. Haver, P. K. Chelikani, and J. L. Buescher Effects of different intermittent peptide YY (3-36) dosing strategies on food intake, body weight, and adiposity in diet-induced obese rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R449 - R458. [Abstract] [Full Text] [PDF]